Roche fact sheet

About Roche
Founded in 1896, headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, infectious disseases, immunology, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roches personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information: www.roche.com. Roches capabilities are augmented by technology collaborations and a constellation of worldwide alliances to help develop individual products and entire product portfolios. Roche has one of the strongest drug development pipelines in the industry with over 30 phase III projects and multiple projects currently in registration. The pipeline overall comprises over 70 new potential medicines and over 20 additional indications for existing medicines. Half of the projects in late-stage development utilise a companion diagnostic test and thus could help advance personalised healthcare.
Pleasanton, CA Ventana Tucson, AZ

The Roche innovation network

South San Francisco, CA

Genentech

Basel, Switzerland

Roche

Tokyo, Japan

Chugai

Madison, WI Indianapolis, IN Branford, MA Rotkreuz, Switzerland

Penzberg, Germany Mannheim, Penzberg, Germany Shanghai, China

Roche Pharma, including Genentech

Roche Diagnostics

Majority shareholdings

Roche is recognised as a leader in Corporate Governance and Sustainability. Roche is listed on the FTSE4 Good Indices and is the 2012 Super Sector leader for healthcare in the Dow Jones Sustainability Indices (DJSI). Roche participates in various humanitarian and educational projects.

Pharma
Pharma is made up of Roche Pharma represented in over 150 countries, Genentech (the Groups U.S. pharma business) and a majority shareholding of Chugai in Japan. Seven of Roches 10 top-selling medicines are manufactured using biotechnology, and biopharmaceuticals account for more than 70% of pharmaceutical sales. Global sales of top 10 medicines in 2012 MabThera/Rituxan1 Herceptin1 Avastin1 Pegasys3 Xeloda1 Lucentis4 Tarceva1 CellCept2 Actemra/RoActemra2 Xolair5 CHF billion 6.7 5.9 5.8 1.6 1.5 1.5 1.3 0.9 0.8 0.7

Sales by region 2012

United States 39% (+7%) Western Europe 22% (-2%) Japan 12% (+2%) CEMAI6 9% (+8%) Latin America 7% (+11%) Asia-Pacic 8% (+15%) Other 3% (-9%)

Sales by therapeutic area 2012

Oncology 61% (+9%) Virology 9% (+14%) Immunology 9% (+5%) Metabolism/bone 5% (-23%) Ophthalmology 4% (-8%) Respiratory diseases 4% (+9%) Cardiovascular diseases 3% (+6%) Renal anemia 2% (-16%) Neuroscience 2% (+1%) Infectious diseases 1% (-1%) Other 1% (-14%)

Diagnostics
Diagnostics is the world leader in in vitro diagnostics; products used to test blood and other body uids and tissue samples to obtain information for the diagnosis, treatment and monitoring of diseases. Its product portfolio ranges from blood glucose meters for people with diabetes and point-of-care testing devices for use in doctors ofces, to high-throughput analysers for hospitals and commercial diagnostic laboratories. The division also supplies state of the art instruments and reagents for life science research.
Sales by region 2012 Sales by business area 2012

Europe, Middle East & Africa (EMEA) 46% (-1%) North America 26% (+3%) Asia-Pacic 15% (+15%) Latin America 8% (+15%) Japan 6% (+7%)

Professional Diagnostics 50% (+8%) Diabetes Care 25% (-4%) Molecular Diagnostics 11% (+4%) Applied Science 7% (-3%) Tissue Diagnostics 6% (+12%)

Italics = growth rates as measured at constant exchange rates 1 Oncology 2 Immunology 3 Infectious diseases

4 Ophthamology 5 Respiratory diseases 6 CEMAI - Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent

Key nancials

Contact information
Investor Relations F. Hoffmann-La Roche Ltd CH-4070 Basel Switzerland Main switchboard: +41 61 688 1111 IR requests: +41 61 688 8880 Fax: +41 61 691 0014 investor.relations@roche.com www.roche.com/investors Dr. Karl Mahler +41 61 687 8503 karl.mahler@roche.com Dr. Sabine Borngraeber +41 61 688 8027 sabine.borngraeber@roche.com Dr. Tamer Farhan +41 61 688 2552 tamer. farhan@roche.com Elhan Webb, CFA +41 61 688 9630 elhan.webb@roche.com

As reported in Swiss Francs (CHF)

Sales 2012 2011 2010 0 Core operating prot 2012 2011 2010 0 Operating free cash ow 2012 2011 2010 12 13 13.7 14.1 14 15 CHF billion 16 17 10 15.4 25 17.2 15.1 16.6 20 35.2 32.8
37.1

10.3 9.7
10.4

45.5 42.5 47.5 50

Dr. Lus Correia +41 61 687 5284 luis.correia@roche.com Dr. Nina Mojas +41 61 687 1300 nina.mojas@roche.com

Per security data as reported in Swiss Francs (CHF)

Core earnings per share (EPS)
2012 2011 2010 0.00 5.00 13.62 12.30 12.78 10.00
7.35

Investor Relations North America Roche Holdings, Inc. Genentech, Inc. 1 DNA Way South San Francisco CA 94080 USA Main number: +1 650 225 5566 Fax: +1 650 225 8326 RocheIRNA@gene.com

15.00

Dividend per share

2012 2011 2010 0.00
Pharmaceuticals

Thomas Kudsk Larsen +1 650 467 2016 larsen.thomas@gene.com Nina Goworek +1 650 467 8737 goworek.nina@gene.com

Stacy Galvin +1 650 225 4150 galvin.stacy@gene.com Dr. Ekaterine Kortkhonjia +1 650 467 5873 kortkhonjia.ekaterine@gene.com

6.80 6.60
4.00 CHF
Diagnostics

8.00
Group

Additional information
This factsheet for investors contains certain forward-looking statements. These forward-looking statements may be identied by words suchas believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reected in forward-looking statements contained in this Annual Report, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) uctuations in currency exchange rates and general nancial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a prot forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Please see www.roche.com or other Roche Group websites for full information on products mentioned. All trademarks mentioned enjoy legal protection. Copyright 5 June 2013 by Roche Investor Relations North America, South San Francisco.